|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
44,500,000 |
Market
Cap: |
203.37(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$4.39 - $19.45 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE silencing technology.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
21,635 |
74,900 |
95,858 |
242,278 |
Total Sell Value |
$110,279 |
$450,123 |
$665,426 |
$3,932,876 |
Total People Sold |
8 |
11 |
12 |
14 |
Total Sell Transactions |
8 |
11 |
13 |
49 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2020-01-15 |
4 |
AS |
$68.97 |
$275,880 |
D/D |
(4,000) |
41,578 |
|
-8% |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2020-01-15 |
4 |
OE |
$5.31 |
$21,240 |
D/D |
4,000 |
45,578 |
|
- |
|
Soteropoulos Paula |
Director |
|
2020-01-07 |
4 |
AS |
$72.18 |
$216,540 |
D/D |
(3,000) |
5,352 |
|
-21% |
|
Kapusta Matthew C |
CEO, CFO, Managing Director |
|
2019-12-18 |
4 |
AS |
$69.94 |
$528,510 |
D/D |
(7,540) |
367,451 |
|
- |
|
Kapusta Matthew C |
CEO, CFO, Managing Director |
|
2019-12-18 |
4 |
OE |
$7.53 |
$55,263 |
D/D |
7,339 |
374,991 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2019-12-16 |
4 |
AS |
$74.37 |
$298,356 |
D/D |
(4,000) |
41,578 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2019-12-16 |
4 |
OE |
$5.31 |
$21,240 |
D/D |
4,000 |
45,578 |
|
- |
|
Soteropoulos Paula |
Director |
|
2019-12-13 |
4 |
AS |
$70.50 |
$141,000 |
D/D |
(2,000) |
8,352 |
|
- |
|
Soteropoulos Paula |
Director |
|
2019-12-13 |
4 |
OE |
$5.37 |
$10,740 |
D/D |
2,000 |
10,352 |
|
- |
|
Soteropoulos Paula |
Director |
|
2019-12-09 |
4 |
AS |
$67.50 |
$168,750 |
D/D |
(2,500) |
8,352 |
|
- |
|
Soteropoulos Paula |
Director |
|
2019-12-06 |
4 |
AS |
$63.69 |
$583,600 |
D/D |
(9,082) |
10,852 |
|
- |
|
Kapusta Matthew C |
CEO, CFO, Managing Director |
|
2019-11-20 |
4 |
AS |
$53.04 |
$429,951 |
D/D |
(8,000) |
367,652 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2019-11-15 |
4 |
AS |
$51.99 |
$208,310 |
D/D |
(4,000) |
41,578 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2019-11-15 |
4 |
OE |
$5.31 |
$21,240 |
D/D |
4,000 |
45,578 |
|
- |
|
Kapusta Matthew C |
CEO, CFO, Managing Director |
|
2019-10-23 |
4 |
AS |
$42.94 |
$345,781 |
D/D |
(8,000) |
375,652 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2019-10-15 |
4 |
AS |
$42.35 |
$169,400 |
D/D |
(4,000) |
41,578 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2019-10-15 |
4 |
OE |
$5.31 |
$21,240 |
D/D |
4,000 |
45,578 |
|
- |
|
Gut Robert |
Chief Medical Officer |
|
2019-09-19 |
4 |
S |
$47.16 |
$224,906 |
D/D |
(4,769) |
35,378 |
|
- |
|
Kapusta Matthew C |
CEO, CFO, Managing Director |
|
2019-09-18 |
4 |
AS |
$46.69 |
$378,486 |
D/D |
(8,000) |
383,652 |
|
- |
|
Van Deventer Sander |
EVP, Research & Product Dev. |
|
2019-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
45,354 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2019-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
41,578 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2019-09-16 |
4 |
AS |
$47.26 |
$189,040 |
D/D |
(4,000) |
26,578 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, Operations |
|
2019-09-16 |
4 |
OE |
$5.31 |
$21,240 |
D/D |
4,000 |
30,578 |
|
- |
|
Kapusta Matthew C |
CEO, CFO, Managing Director |
|
2019-08-21 |
4 |
AS |
$56.48 |
$451,840 |
D/D |
(8,000) |
391,230 |
|
- |
|
Kuta Alexander Edward Iii |
Executive VP, OperationsOffice |
|
2019-08-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
26,578 |
|
- |
|
336 Records found
|
|
Page 10 of 14 |
|
|